- Home
- JPI vs MRVI Comparison
JPI vs MRVI Comparison
Compare JPI & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPI
- MRVI
- Stock Information
- Founded
- JPI 2012
- MRVI 2014
- Country
- JPI United States
- MRVI United States
- Employees
- JPI N/A
- MRVI N/A
- Industry
- JPI Finance Companies
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- JPI Finance
- MRVI Health Care
- Exchange
- JPI Nasdaq
- MRVI Nasdaq
- Market Cap
- JPI 278.6M
- MRVI 262.9M
- IPO Year
- JPI N/A
- MRVI 2020
- Fundamental
- Price
- JPI $20.47
- MRVI $2.03
- Analyst Decision
- JPI
- MRVI Hold
- Analyst Count
- JPI 0
- MRVI 9
- Target Price
- JPI N/A
- MRVI $6.54
- AVG Volume (30 Days)
- JPI 54.7K
- MRVI 1.7M
- Earning Date
- JPI 01-01-0001
- MRVI 05-12-2025
- Dividend Yield
- JPI 6.15%
- MRVI N/A
- EPS Growth
- JPI N/A
- MRVI N/A
- EPS
- JPI N/A
- MRVI N/A
- Revenue
- JPI N/A
- MRVI $259,185,000.00
- Revenue This Year
- JPI N/A
- MRVI N/A
- Revenue Next Year
- JPI N/A
- MRVI $14.23
- P/E Ratio
- JPI N/A
- MRVI N/A
- Revenue Growth
- JPI N/A
- MRVI N/A
- 52 Week Low
- JPI $16.02
- MRVI $1.67
- 52 Week High
- JPI $19.12
- MRVI $11.56
- Technical
- Relative Strength Index (RSI)
- JPI 66.50
- MRVI 47.81
- Support Level
- JPI $19.81
- MRVI $1.96
- Resistance Level
- JPI $20.46
- MRVI $2.16
- Average True Range (ATR)
- JPI 0.39
- MRVI 0.12
- MACD
- JPI 0.10
- MRVI 0.05
- Stochastic Oscillator
- JPI 100.00
- MRVI 69.77
About JPI Nuveen Preferred and Income Term Fund of Beneficial Interest
Nuveen Preferred and Income Term Fund is a closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The company's products include mutual funds, closed-end funds, Exchange-traded funds, Multi-asset model portfolios, and others.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.